$2.34 Billion is the total value of Camber Capital Management LP's 26 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 39.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Buy | SPDR S&P 500 ETF TRput | $581,440,000 | +114.3% | 2,000,000 | +100.0% | 24.88% | +138.4% |
| AGN | Sell | ALLERGAN PLC | $171,432,000 | +2.3% | 900,000 | -10.4% | 7.34% | +13.8% |
| HCA | Sell | HCA HEALTHCARE INC | $139,120,000 | +0.4% | 1,000,000 | -25.9% | 5.95% | +11.7% |
| MYL | Buy | MYLAN N V | $137,250,000 | +51.9% | 3,750,000 | +50.0% | 5.87% | +69.0% |
| TSRO | Buy | TESARO INC | $136,535,000 | +22.8% | 3,500,000 | +40.0% | 5.84% | +36.6% |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $115,056,000 | +14.7% | 900,000 | 0.0% | 4.92% | +27.6% | |
| BIIB | Sell | BIOGEN INC | $105,993,000 | -18.8% | 300,000 | -33.3% | 4.54% | -9.7% |
| MCK | New | MCKESSON CORP | $99,488,000 | – | 750,000 | +100.0% | 4.26% | – |
| NKTR | Sell | NEKTAR THERAPEUTICS | $91,440,000 | -6.4% | 1,500,000 | -25.0% | 3.91% | +4.1% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS INC | $78,850,000 | -20.7% | 2,075,000 | -5.7% | 3.37% | -11.8% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $75,715,000 | +21.2% | 2,878,890 | -5.8% | 3.24% | +34.8% |
| PRGO | Buy | PERRIGO CO PLC | $70,800,000 | +5.0% | 1,000,000 | +8.1% | 3.03% | +16.8% |
| ATRA | ATARA BIOTHERAPEUTICS INC | $66,987,000 | +12.5% | 1,620,000 | 0.0% | 2.87% | +25.1% | |
| BKD | BROOKDALE SENIOR LIVING | $63,895,000 | +8.1% | 6,500,000 | 0.0% | 2.73% | +20.3% | |
| EVHC | Sell | ENVISION HEALTHCARE CORP | $61,964,000 | -14.7% | 1,355,000 | -17.9% | 2.65% | -5.1% |
| MDCO | MEDICINES CO | $59,820,000 | -18.5% | 2,000,000 | 0.0% | 2.56% | -9.3% | |
| AMAG | AMAG PHARMACEUTICALS INC | $53,000,000 | +2.6% | 2,650,000 | 0.0% | 2.27% | +14.1% | |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $51,398,000 | +13.0% | 1,750,000 | +75.0% | 2.20% | +25.7% |
| THC | Sell | TENET HEALTHCARE CORP | $44,113,000 | -41.6% | 1,550,000 | -31.1% | 1.89% | -35.0% |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $34,388,000 | – | 750,000 | +100.0% | 1.47% | – |
| KTWO | Sell | K2M GROUP HLDGS INC | $27,370,000 | -39.2% | 1,000,000 | -50.0% | 1.17% | -32.4% |
| ZYME | Buy | ZYMEWORKS INC | $21,556,000 | +16.7% | 1,373,000 | +9.8% | 0.92% | +29.7% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $20,217,000 | +2.3% | 291,600 | +11.7% | 0.86% | +13.8% |
| ELGX | ENDOLOGIX INC | $17,763,000 | -66.3% | 9,300,000 | 0.0% | 0.76% | -62.5% | |
| STRO | New | SUTRO BIOPHARMA INC | $9,000,000 | – | 600,000 | +100.0% | 0.38% | – |
| SGRY | SURGERY PARTNERS INC | $2,229,000 | +10.7% | 135,084 | 0.0% | 0.10% | +23.4% | |
| ENDP | Exit | ENDO INTL PLC | $0 | – | -2,500,000 | -100.0% | -0.91% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -1,250,000 | -100.0% | -1.25% | – |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -1,900,000 | -100.0% | -1.36% | – |
| CSII | Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -1,647,677 | -100.0% | -2.05% | – |
| MYGN | Exit | MYRIAD GENETICS INC | $0 | – | -1,500,000 | -100.0% | -2.16% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -1,200,000 | -100.0% | -2.41% | – |
| CELG | Exit | CELGENE CORPcall | $0 | – | -1,000,000 | -100.0% | -3.06% | – |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -650,000 | -100.0% | -4.22% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -2,000,000 | -100.0% | -4.26% | – |
| GHDX | Exit | GENOMIC HEALTH INC | $0 | – | -2,458,100 | -100.0% | -4.77% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.